A Prospective Randomized Clinical Trial on 90Yttrium Trans-Arterial Radio-Embolization (Therasphere®) vs. Standard Of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)

ID Number 14-0406

Principal Investigator(s)
Myron E Schwartz

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to examine whether TheraSphere is better than the current standard treatment for liver cancer (sorafenib) alone. Better means slowing or stopping the growth of liver tumors without experiencing a significant increase in number or severity of side effects. You are being asked to voluntarily participate in this study because you have been diagnosed and need treatment for a liver cancer that cannot be removed by surgery. There are no other treatments being evaluated in this study.

Contact Information
Cidney Schultz

Recruiting Patients: No